Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Abstract In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrat...
Main Authors: | Seyed Hossein Kiaie, Naime Majidi Zolbanin, Armin Ahmadi, Rafieh Bagherifar, Hadi Valizadeh, Fatah Kashanchi, Reza Jafari |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-06-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-022-01478-7 |
Similar Items
-
Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection
by: Tao Chen, et al.
Published: (2022-05-01) -
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
by: Xavier Sáez-Llorens, et al.
Published: (2022-08-01) -
The mRNA-LNP vaccines – the good, the bad and the ugly?
by: Botond Z. Igyártó, et al.
Published: (2024-02-01) -
ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
by: Owen Daly, et al.
Published: (2023-06-01) -
Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety
by: Irena Vlatkovic
Published: (2021-05-01)